Aktienanalyse zu Evolus Inc (EOLS)EOLSEvolus Inc

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Evolus Inc is a good buy right now due to its recent strong revenue growth of 21% in Q2, surpassing expectations, and a positive adjusted EBITDA of $4.7 million for the third consecutive quarter. Additionally, the stock has shown a significant 52.05% increase over the last 20 days, indicating strong momentum. However, the main risk is the high forward P/E ratio of 80.65, which suggests that the stock may be overvalued if growth expectations are not met.

4 analysts cover EOLS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 19.25.